Discrepant MR and [18F]Fluoroethyl-l-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure

Discrepant MR and [18F]Fluoroethyl-l-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure

Antiangiogenic treatment using bevacizumab may cause difficulties in distinguishing between antivascular and true antitumor effects when using MRI response criteria based on changes of contrast enhancement (i.e., Macdonald criteria). Furthermore, more precise tumor response assessment criteria (i.e....

Full description

Bibliographic Details
Main Authors: Norbert Galldiks, Christian P. Filss, Roland Goldbrunner, Karl-Josef Langen
Format: Article
Language:English
Published: Karger Publishers 2012-09-01
Series:Case Reports in Oncology
Subjects:
Metabolically active tumor volume
[18F]Fluoroethyl-l-tyrosine
Amino acid PET
RANO criteria
Volume-of-interest analysis
Online Access:http://www.karger.com/Article/FullText/342480

Internet

http://www.karger.com/Article/FullText/342480

Similar Items